ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the First Global Life Sciences Conference to be held on September 16-17, 2013 in Warsaw, Poland. Mr. Riley is scheduled to present at 11:15 a.m. (Central European Summer Time)/5:15 a.m. (Eastern Time) on Monday, September 16, 2013 at the Warsaw Stock Exchange.
(Logo: https://photos.prnewswire.com/prnh/20130522/MM19465LOGO )
A live webcast of Synthetic Biologics’ presentation can be accessed by logging onto the internet at http://www.wdmcapital.com/en/strony/lsc/live_webcast.html. After the presentation, a replay will be archived and accessible for 30 days at the same website.
Mr. Riley, as well as Synthetic Biologics’ CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with conference attendees. To arrange a one-on-one meeting with Synthetic Biologics, please contact Wojciech Grzegorczyk at email@example.com or by phone +48 784 094 599.
WDM Capital, a prominent small cap investment bank in Central and Eastern Europe, is organizing the conference in partnership with the Warsaw Stock Exchange and Deloitte. For more information visit: http://lscwarsaw.com.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To download Synthetic Biologics’ investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.
SOURCE Synthetic Biologics, Inc.
Released September 10, 2013